IL2 and amyotrophic lateral sclerosis: Although it is ethically difficult to do new studies exclusively of riluzole, studies of this drug embedded within other clinical trials have been completed (eg, the study of dexpramipexole in ALS; EMPOWER, NCT01281189),32 or are underway (eg, a study of low-dose interleukin-2 in ALS; MIROCALS, NCT03039673).